Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 1/20 | 0.60 |
| ▸ | SLC6A2 | P23975 | 5/20 | 0.53 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.53 |
| ▸ | CHRNA1 | P02708 | 2/20 | 0.53 |
| ▸ | CHRNG | P07510 | 2/20 | 0.53 |
| ▸ | CHRNB1 | P11230 | 2/20 | 0.53 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.53 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.53 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.53 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.53 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.53 |
| ▸ | CHRND | Q07001 | 2/20 | 0.53 |
| ▸ | ITGA5 | P08648 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | HRH1 | P35367 | 1/20 | 0.53 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.53 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.53 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8867285 | 0.84 | PARP1 (0.59) | PARP1SLC6A2SLC6A3CHRNA1CHRNG | |
| SCHEMBL10435720 | 0.83 | PARP1 (0.58) | PARP1SLC6A2SLC6A3CHRNA1CHRNG | |
| SCHEMBL9041221 | 0.83 | SLC6A2 (0.59) | PARP1SLC6A2SLC6A3CHRNA1CHRNG | |
| SCHEMBL3852863 | 0.83 | SLC6A2 (0.59) | PARP1SLC6A2SLC6A3CHRNA1CHRNG | |
| SCHEMBL3851904 | 0.83 | SLC6A2 (0.59) | PARP1SLC6A2SLC6A3CHRNA1CHRNG | |
| Hydrochloric Acid SCHEMBL3855294 | 0.81 | SLC6A2 (0.60) | PARP1SLC6A2SLC6A3CHRNA1CHRNG | |
| SCHEMBL11769927 | 0.81 | SLC6A2 (0.61) | PARP1SLC6A2SLC6A3CHRNA1CHRNG | |
| SCHEMBL31268571 | 0.81 | SLC6A2 (0.61) | PARP1SLC6A2SLC6A3CHRNA1CHRNG | |
| SCHEMBL28473881 | 0.81 | PARP1 (0.55) | PARP1SLC6A2SLC6A3CHRNA1CHRNG | |
| SCHEMBL8400060 | 0.79 | PARP1 (0.58) | PARP1SLC6A2SLC6A3CHRNB2CHRNB4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070197522-A1 | Dpp-iv inhibitors | SANTHERA PHARMACEUTICALS (SCHWEIZ) GMBH (CH) | 2007-08-23 | — | — | US | disclosed |
| US-20070099927-A1 | Aminoalkyl-pyrazinones and-pyridones as thrombin inhibitors | SANTHERA PHARMACEUTICALS (SCHWEIZ) GMBH (CH) | 2007-05-03 | — | — | US | disclosed |
| EP-1758861-A1 | DPP-IV INHIBITORS | Santhera Pharmaceuticals (Schweiz) AG (CH) | 2007-03-07 | — | — | EP | disclosed |
| WO-2006066899-A1 | NOVEL THROMBIN INHIBITORS | SANTHERA PHARMACEUTICALS (SCHWEIZ) AG (CH) | 2006-06-29 | — | — | WO | disclosed |
| EP-1674464-A1 | Novel thrombin inhibitors | Santhera Pharmaceuticals (Schweiz) GmbH (CH) | 2006-06-28 | — | — | EP | disclosed |
| WO-2005095343-A1 | DPP-IV INHIBITORS | SANTHERA PHARMACEUTICALS (SCHWEIZ) GMBH (CH) | 2005-10-13 | — | — | WO | disclosed |
| WO-2005040137-A1 | AMINOALKYL-PYRAZINONES AND -PYRIDONES AS THROMBIN INHIBITORS | SANTHERA PHARMACEUTICALS (SCHWEIZ) GMBH (CH) | 2005-05-06 | — | — | WO | disclosed |
| EP-0663899-B1 | SUBSTITUTED KYNURENINES, A PROCESS FOR THEIR PREPARATION, AND USE AS MEDICAMENTS | UNIV MARYLAND (US) | 1999-06-30 | — | — | EP | disclosed |
| EP-0919538-A1 | Substituted kynurenines, a process for their preparation, and use as medicaments | THE UNIVERSITY OF MARYLAND AT BALTIMORE (US) | 1999-06-02 | — | — | EP | disclosed |
| US-5786508-A | ENZYME INHIBITOR; COGNITION ACTIVATOR | PHARMACIA & UPJOHN S.P.A. (IT) | 1998-07-28 | — | — | US | disclosed |
| US-5708030-A | COGNITION ACTIVATORS, PERINATAL BRAIN DISORDERS | UNIVERSITY OF MARYLAND (US) | 1998-01-13 | — | — | US | disclosed |
| US-5519055-A | ENZYME INHIBITORS | UNIVERSITY OF MARYLAND AT BALTIMORE (US) | 1996-05-21 | — | — | US | disclosed |
| EP-0663899-A4 | SUBSTITUTED KYNURENINES, A PROCESS FOR THEIR PREPARATION, AND USE AS MEDICAMENTS. | UNIV MARYLAND (US) | 1996-01-17 | — | — | EP | disclosed |
| EP-0663899-A1 | SUBSTITUTED KYNURENINES, A PROCESS FOR THEIR PREPARATION, AND USE AS MEDICAMENTS | THE UNIVERSITY OF MARYLAND AT BALTIMORE (US) | 1995-07-26 | — | — | EP | disclosed |
| WO-1995004714-A1 | SUBSTITUTED KYNURENINES, A PROCESS FOR THEIR PREPARATION, AND USE AS MEDICAMENTS | UNIVERSITY OF MARYLAND AT BALTIMORE (US) | 1995-02-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197522-A1 | Dpp-iv inhibitors | DPP7, DPP4, DPP3 | PARP1 1989/4885SLC6A2 1134/4885SLC6A3 349/4885 |
| US-20070099927-A1 | Aminoalkyl-pyrazinones and-pyridones as thrombin inhibitors | F2, F12, SERPINC1 | PARP1 210/4885SLC6A2 4745/4885SLC6A3 4376/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.